Top Markets
Coin of the day
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
株式のランク #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
株価
$0.41
最終同期: 2025-01-23
時価総額
$1.08M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 CohBar, Inc. (CWBR)

カテゴリー

CohBar, Inc.(CWBR)の発行済株式数
June 2023 時点の発行済株式数 2.91M
CohBar, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 2.91M です。December 2021 の終わりには、同社は 2.22M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
CohBar, Inc.(CWBR)の発行済株式数の履歴(2012 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 2.91M 0.31%
2022 2.90M 30.54%
2021 2.22M 36.45%
2020 1.63M 14.02%
2019 1.43M 3.78%
2018 1.38M 10.09%
2017 1.25M 13.13%
2016 1.10M 3.37%
2015 1.07M 80.48%
2014 591.75K 37.62%
2013 430.00K 6.70%
2012 403.00K 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M 8,634.31%
US
62.19M 2,039.22%
NL
- -
CH
- -
KR
0.00 -100.00%
BE